Detalles de la búsqueda
1.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Ann Rheum Dis
; 83(3): 360-371, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932009
2.
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
N Engl J Med
; 365(17): 1586-96, 2011 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-22029980
3.
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Eur J Pharm Sci
; 172: 106155, 2022 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247543
4.
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
Clin Transl Sci
; 14(5): 1756-1768, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33834628
5.
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
J Am Acad Dermatol
; 58(1): 106-15, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17936411
6.
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Dermatology
; 216(3): 260-70, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18187944
7.
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
Crit Care Med
; 32(11): 2173-82, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15640628
Resultados
1 -
7
de 7
1
Próxima >
>>